Last reviewed · How we verify
150% bolus insulin correction — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
150% bolus insulin correction (150% bolus insulin correction) — LMC Diabetes & Endocrinology Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 150% bolus insulin correction TARGET | 150% bolus insulin correction | LMC Diabetes & Endocrinology Ltd. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 150% bolus insulin correction CI watch — RSS
- 150% bolus insulin correction CI watch — Atom
- 150% bolus insulin correction CI watch — JSON
- 150% bolus insulin correction alone — RSS
Cite this brief
Drug Landscape (2026). 150% bolus insulin correction — Competitive Intelligence Brief. https://druglandscape.com/ci/150-bolus-insulin-correction. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab